RIDGELAND, Miss., Feb. 9, 2005 (PRIMEZONE) -- Knobias recently conducted an interview, with Dr. Stephen Roberts, CEO of GelStat, Inc. (OTCBB:GSAC). Below are links to the full interview and transcript.
Dr. Stephen Roberts outlined the following highlights during the interview.
Aging Competition: Dr. Roberts stated, "I think you will agree that most of the products that you can look at are the same ones that were available, say, ten years ago." Dr. Roberts then went on to say, "we see a significant unmet need there, not only because these products are old, but because they simply don't work very well."
Product Efficacy: Dr. Roberts also commented, "the OTC products that are presently available are effective only about 25 percent of the time. So there is clearly room for substantial improvement. We have delivered that with GelStat Migraine because we have clinical trials demonstrating 83 percent efficacy."
On Expanding to International Markets: In addition, Dr. Roberts stressed the point, "So I have talked about a 2.6 billion dollar market, 600 million units, when we go international with GelStat Migraine, which we will, you can roughly triple the size of those potential markets."
The interview is available at http://cobrand.knobias.com/templates/aware/view/gelstat.htm?ticker=GSAC
The full transcript is available at http://cobrand.knobias.com/clipreport/reports/transcripts/gelstat_020105.pdf
About GelStat, Inc.
GelStat Corporation is a consumer health care company dedicated to the cost-effective development and marketing of advanced OTC health care products. Development efforts are focused on very large markets where GelStat products can offer improved efficacy, safety, and/or convenience over existing OTCs.
About Knobias Issuer Services
Companies that are interviewed pay an all-inclusive fee of up to $1,800 for media services in the form of CEO interviews, data reports and press packages. All statements are the opinion of the companies featured and are not a solicitation or recommendation to buy, sell, or hold securities. Please note that Knobias is not a registered investment advisor or a broker dealer. Knobias accepts only a flat cash fee and does not accept any forward looking considerations based on performance or any stock or position within the companies that we do business with.
Forward-Looking Safe Harbor Statement:
To the extent that this release discusses any expectations concerning future plans, financial results or performance, such statements are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, and are subject to substantial risks and uncertainties. Actual results could differ materially from those anticipated in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward looking statements, which speak only as of the date hereof and reflect only management's belief and expectations based upon presently available information. These statements, and other forward looking statements, are not guarantees of future performance and involve risks and uncertainties. Knobias assumes no obligation to update any of the forward-looking statements in this release.